Form 10-Q Y-mAbs Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Y-mAbs Therapeutics (YMAB) PT Lowered to $25 at BMO Capital
August 12, 2024 4:08 PM EDTBMO Capital analyst Etzer Darout lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $25.00 (from $26.00) while maintaining a Outperform rating.
The analyst comments "YMAB reported 2Q24 total revenues of $22.8M, a touch below FactSet consensus (-0.9%) but ahead of our estimate (+3.6%).... More
